Event Details
| Title: | Digestive Disease Week® 2006 (DDW) |
| Date: | Saturday, May 20, 2006 through Thursday, May 25, 2006 |
| File: | Description: |
| Targan and Sandborn DDW 2006 Abstract ENCORE | |
 | Natalizumab Induces Sustained Response and Remission in Patients with Active Crohn's Disease: Results from the ENCORE Trial |
 | |
| |
| Sandborn DDW 2006 Abstract Safety Assessment | |
| A Safety Evaluation for Progressive Multifocal Leukoencephalopathy (PML) in Greater Than 3,500 Patients with Crohn's Disease (CD), Multiple Sclerosis (MS), and Rheumatoid Arthritis (RA) Previously Treated with Natalizumab in Clinical Trials |
| |
| |
| Feagan DDW 2006 Abstract QoL | |
| Maintenance Treatment with Natalizumab Improves the Health Related Quality of Life (HRQOL) in Crohn's Disease Patients |
| |
| |
| Panaccione DDW 2006 Abstract Long-term Efficacy | |
| Natalizumab Maintains Remission in Patients with Moderately to Severely Active Crohn's Disease for up to 2-Years: Results From an Open-label Extension Study |
| |
| |
| Sandborn DDW 2006 Abstract Immunosuppressant Use | |
| Maintenance Therapy with Natalizumab Does not Require use of Concomitant Immunosuppressants for Sustained Efficacy in Patients with Active Crohn's Disease: Results from the ENACT-2 Study |